Actavis Group hf. and Abrika Pharmaceuticals, Inc., In the Matter of

The Commission prevented a merger-to-monopoly in the sale of generic isradipine capsules by challenging the proposed $235 million purchase of Abrika Pharmaceuticals, Inc., by the Actavis Group, an international generic pharmaceuticals company. To maintain competition in the market for this important generic drug, used to lower blood pressure and to treat hypertension, ischemia, and depression, the consent order requires the divestiture of all rights and assets necessary to produce, market, and sell generic isradipine to Cobalt Laboratories, Inc.